Avanos Medical (AVNS) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 36.84%. A quarter ago, it was expected that this medical technology company would post earnings of $0.40 per share when it actually produced earnings of $0.43, delivering a surprise of 7.50%.Over the last four quart ...

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.29, delivering a surprise of -7.41%.Over the last four quarters, the company has ...

Group 1: Earnings Performance - AdaptHealth Corp. reported quarterly earnings of $0.01 per share, matching the Zacks Consensus Estimate, compared to $0.02 per share a year ago [1] - The company posted revenues of $777.88 million for the quarter, exceeding the Zacks Consensus Estimate by 1.72%, but down from $792.5 million year-over-year [2] - Over the last four quarters, AdaptHealth has surpassed consensus EPS estimates three times [1][2] Group 2: Stock Performance and Outlook - AdaptHealth shares have declined approximately 8.6% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.28 for the coming quarter and $1.12 for the current fiscal year [4][7] - The current Zacks Rank for AdaptHealth is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which AdaptHealth belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Premier, Inc. (PINC) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 41.94%. A quarter ago, it was expected that this company would post earnings of $0.29 per share when it actually produced earnings of $0.27, delivering a surprise of -6.90%.Over the last four quarters, the company ha ...

Group 1: Earnings Performance - Celsius Holdings Inc. reported quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.20 per share, and down from $0.27 per share a year ago, representing an earnings surprise of -10% [1] - The company posted revenues of $329.28 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.62%, and down from $355.71 million year-over-year [2] Group 2: Stock Performance and Outlook - Celsius shares have increased approximately 28.7% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $633.89 million, and for the current fiscal year, it is $0.99 on revenues of $2.18 billion [7] Group 3: Industry Context - The Zacks Industry Rank for Food - Miscellaneous is currently in the top 31% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Waters (WAT) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.35%. A quarter ago, it was expected that this maker of products used in drug discovery and development would post earnings of $4.02 per share when it actually produced earnings of $4.10, delivering a surprise of 1.99%.Over ...

Primoris Services (PRIM) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 36.11%. A quarter ago, it was expected that this construction contractor would post earnings of $0.73 per share when it actually produced earnings of $1.13, delivering a surprise of 54.79%.Over the last four quar ...

Core Viewpoint - Interparfums reported quarterly earnings of $1.32 per share, exceeding the Zacks Consensus Estimate of $1.13 per share, and showing an increase from $1.27 per share a year ago, representing an earnings surprise of 16.81% [1][2] Financial Performance - The company achieved revenues of $338.82 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.47% and increasing from $323.96 million year-over-year [2] - Over the last four quarters, Interparfums has consistently surpassed consensus EPS estimates [2] Stock Performance - Interparfums shares have declined approximately 14.1% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current Zacks Rank for Interparfums is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $1.24 on revenues of $358.05 million, and for the current fiscal year, it is $5.34 on revenues of $1.51 billion [7] - The trend of estimate revisions for Interparfums is currently mixed, which may change following the recent earnings report [6] Industry Context - The Consumer Products - Discretionary industry, to which Interparfums belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, indicating potential challenges ahead [8]

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this drug developer would post earnings of $0.37 per share when it actually produced earnings of $0.26, delivering a surprise of -29.73%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Corcept, which bel ...

Core Viewpoint - EverQuote (EVER) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing significant growth from $0.05 per share a year ago, indicating strong performance in the insurance sector [1][2]. Financial Performance - The company achieved revenues of $166.63 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.41%, and up from $91.07 million year-over-year [2]. - Over the last four quarters, EverQuote has consistently exceeded consensus EPS estimates, demonstrating a strong earnings performance [2]. Stock Performance - EverQuote shares have increased approximately 33.6% since the beginning of the year, contrasting with a decline of -3.3% in the S&P 500 [3]. - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating expectations for continued outperformance in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $150.15 million, and for the current fiscal year, it is $1.20 on revenues of $626.23 million [7]. - The insurance industry, particularly the Insurance - Multi line sector, is currently ranked in the top 25% of Zacks industries, suggesting a favorable environment for stock performance [8].